Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of pixantrone (BBR 2778) [Cell Therapeutics] in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma

Next Previous
X
Search
Trial Profile

A phase I/II study of pixantrone (BBR 2778) [Cell Therapeutics] in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixantrone (Primary) ; Cyclophosphamide; Prednisone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Apr 2011 Results have been published in Leukaemia & Lymphoma, according to a Cell Therapeutics media release.
    • 19 Jan 2007 Status change
    • 18 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top